{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010300","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.068111+00:00","generated_at":"2026-06-04T14:26:23.684678+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PURE Bioscience Q2 net product sales $325K, net loss $1.0M; shifting to distributor model","bullets":["Net product sales $325K in Q2 FY2024, down 18% from $396K YoY; net loss $1.002M vs $1.060M.","Q2 net loss per share ($0.01); six-month net product sales $1.043M, up 21% from $863K.","CEO cites unexpected interruption in product flow to one major customer as cause of revenue shortfall.","Company shifting from direct sales to distributor model to expand market coverage and accelerate growth.","New food segments and dairy/animal health show interest; registered to exhibit at IAFP July 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010300","json":"https://secwatch.observer/filing/0001493152-24-010300.json","markdown":"https://secwatch.observer/filing/0001493152-24-010300.md","text":"https://secwatch.observer/filing/0001493152-24-010300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224010300/0001493152-24-010300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224010300/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:26:23.684678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57cc7df6935e812beeb37165521b33b95e84bcf4","claim":"PURE BIOSCIENCE, INC. reported the fiscal second quarter ended January 31, 2024 results: revenue $325,000, net income $1,002,000, EPS ($0.01) per share.","evidence_excerpt":"Net product sales were $325,000 and $396,000 for the fiscal second quarter ended January 31, 2024 and 2023, respectively. The decrease of $71,000 was attributable to decreased sales across our end user network. ● Net loss for the fiscal second quarter ended January 31, 2024 was $1,002,000, compared to $1,060,000 for the fiscal second quarter ended January 31, 2023. ● Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2024 was $938,000, compared to $993,000 for the fiscal second quarter ended January 31, 2023. ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2024 and 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224010300/0001493152-24-010300-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal second quarter ended January 31, 2024"},{"label":"Revenue","value":"$325,000"},{"label":"Net income","value":"$1,002,000"},{"label":"EPS","value":"($0.01) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"812cd1bd51b8037b7242c4f73fd54d220bc8f839","claim":"PURE BIOSCIENCE, INC. reported the six months ended January 31, 2024 results: revenue $1,043,000, net income $1,737,000, EPS ($0.02) per share.","evidence_excerpt":"Net product sales were $1,043,000 and $863,000 for the six months ended January 31, 2024 and 2023, respectively. The increase of $180,000 was attributable to increased sales across our end user and distribution network. ● Net loss for the six months ended January 31, 2024 was $1,737,000, compared to $2,053,000 for the six months ended January 31, 2023. ● Net loss, excluding share-based compensation, for the six months ended January 31, 2024 was $1,593,000, compared to $1,842,000 for the six months ended January 31, 2023. ● Net loss per share was ($0.02) for the six months ended January 31, 2024 and 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224010300/0001493152-24-010300-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended January 31, 2024"},{"label":"Revenue","value":"$1,043,000"},{"label":"Net income","value":"$1,737,000"},{"label":"EPS","value":"($0.02) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}